Voyager Therapeutics stock trades at EUR 1.71 on Thursday

Published on 11/05/2026 at 14:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Voyager Therapeutics stock is in focus as the biotechnology company advances genetic medicines for neurological disease. Its pipeline includes Alzheimer’s programs.

Clinical calendar remains in focus

Voyager Therapeutics develops genetic medicines for neurological diseases.
The company says its pipeline includes Alzheimer’s disease and other central nervous system programs.
CTAD 2026 poster presentations remain the next identified clinical-calendar item.

VYGR, US92915B1061, Illustration mit AI erstellt.

Voyager Therapeutics stock traded at EUR 1.71 on Lang & Schwarz at 14:09 CET on Thursday, November 5, 2026.

Genetic medicines remain core focus

Voyager Therapeutics describes itself as a biotechnology company developing genetic medicines for neurological diseases. Its investor relations page lists programs targeting Alzheimer’s disease, Friedreich’s ataxia, Parkinson’s disease and amyotrophic lateral sclerosis.

The company says many programs are based on its TRACER AAV capsid discovery platform, while others are advancing with partners including Alexion, AstraZeneca Rare Disease, Novartis and Neurocrine Biosciences.

CTAD presentations remain ahead

Voyager’s investor-relations page lists an October 27 announcement covering poster presentations for its VY1706 tau-targeted gene therapy and VY7523 anti-tau antibody at CTAD 2026. The clinical calendar gives investors a defined near-term event to monitor alongside pipeline progress.

Investors can follow the real-time quote of Voyager Therapeutics stock for subsequent trading updates.